Literature DB >> 30720699

Major Depressive Disorder in Medical Illness: A Review of Assessment, Prevalence, and Treatment Options.

Robyn Thom1, David A Silbersweig, Robert J Boland.   

Abstract

Major depression, as well as other depressive disorders, is commonly comorbid with other medical illnesses, particularly chronic and systemic medical illnesses. The co-occurrence of the disorders is so common that it challenges our notions of the meaning of comorbidity and our desire to neatly separate psychiatric and medical illnesses. The overlap between symptoms of physical illness and the neurovegetative symptoms of major depression and the initial normative emotional response to physical illness add to the challenge of accurate diagnosis and timely treatment of depression in the medically ill. We review the literature on the comorbidity of depression and the various medical illnesses, including diagnostic and treatment approaches. The differential diagnosis for major depression among medically ill patients should include delirium and medication-induced symptoms. We suggest that major depression itself may be best conceptualized as a systemic illness whose pathophysiology overlaps with other systemic medical illnesses. The initial treatment strategies for major depression in medical illness are like those for the general population; however, the comorbid medical illnesses may interfere with remission. To illustrate these points, we describe a patient with clinical characteristics covered in this review who experienced major depression as well as several chronic illnesses, including hypersensitivity pneumonitis, multiple sclerosis, chronic pain due to degenerative joint disease, and diabetes mellitus.

Entities:  

Mesh:

Year:  2019        PMID: 30720699     DOI: 10.1097/PSY.0000000000000678

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  7 in total

1.  Chemokine (C-C motif) ligand 5 (RANTES) concentrations in the peripheral blood of patients with a depressive disorder.

Authors:  Elżbieta Małujło-Balcerska; Anna Kumor-Kisielewska; Janusz Szemraj; Tadeusz Pietras
Journal:  Pharmacol Rep       Date:  2022-03-16       Impact factor: 3.919

2.  First-onset major depression during the COVID-19 pandemic: A predictive machine learning model.

Authors:  Daniela Caldirola; Silvia Daccò; Francesco Cuniberti; Massimiliano Grassi; Alessandra Alciati; Tatiana Torti; Giampaolo Perna
Journal:  J Affect Disord       Date:  2022-04-27       Impact factor: 6.533

3.  East African HIV care: depression and HIV outcomes.

Authors:  S M Meffert; T C Neylan; C E McCulloch; L Maganga; Y Adamu; F Kiweewa; J Maswai; J Owuoth; C S Polyak; J A Ake; V G Valcour
Journal:  Glob Ment Health (Camb)       Date:  2019-05-31

4.  Preferences for life-sustaining treatment in Korean adults: a cross-sectional study.

Authors:  HyunChul Youn; Suk-Young Lee; Han-Yong Jung; Shin-Gyeom Kim; Seung-Hyun Kim; Hyun-Ghang Jeong
Journal:  BMJ Open       Date:  2021-01-22       Impact factor: 2.692

5.  Portal Vein Thrombosis Is Associated with an Increased Incidence of Depression and Anxiety Disorders.

Authors:  Simon Johannes Gairing; Peter Robert Galle; Jörn M Schattenberg; Karel Kostev; Christian Labenz
Journal:  J Clin Med       Date:  2021-12-02       Impact factor: 4.241

6.  Impact of Antidepressants on Cardiac Events and All-Cause Mortality in Parkinson's Disease: A National Data-Linkage Study.

Authors:  Khalid Orayj
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-30       Impact factor: 2.570

Review 7.  Vitamin E, Alpha-Tocopherol, and Its Effects on Depression and Anxiety: A Systematic Review and Meta-Analysis.

Authors:  Ainsley Ryan Yan Bin Lee; Areeba Tariq; Grace Lau; Nicholas Wee Kiat Tok; Wilson Wai San Tam; Cyrus Su Hui Ho
Journal:  Nutrients       Date:  2022-02-03       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.